癌症研究
细胞生物学
配体(生物化学)
内化
信号转导
癌细胞
受体
抗体-药物偶联物
细胞毒性
化学
抗体
生物
癌症
单克隆抗体
免疫学
生物化学
体外
遗传学
作者
Kenneth G. Geles,Yijie Gao,Andreas Giannakou,Latha Sridharan,Ting-Ting Yamin,Jing Zhang,Riyez Karim,Joel Bard,Nicole Piche‐Nicholas,Manoj B. Charati,Andreas Maderna,Judy Lucas,Jonathon Golas,Magali Guffroy,Steven Robert Pirie-Shepherd,Marc D. Roy,Jessie Qian,Tania Franks,Wenyan Zhong,Christopher J. O’Donnell
标识
DOI:10.1016/j.xcrm.2021.100279
摘要
Aberrant NOTCH3 signaling and overexpression is oncogenic, associated with cancer stem cells and drug resistance, yet therapeutic targeting remains elusive. Here, we develop NOTCH3-targeted antibody drug conjugates (NOTCH3-ADCs) by bioconjugation of an auristatin microtubule inhibitor through a protease cleavable linker to two antibodies with differential abilities to inhibit signaling. The signaling inhibitory antibody rapidly induces ligand-independent receptor clustering and internalization through both caveolin and clathrin-mediated pathways. The non-inhibitory antibody also efficiently endocytoses via clathrin without inducing receptor clustering but with slower lysosomal co-localization kinetics. In addition, DLL4 ligand binding to the NOTCH3 receptor mediates transendocytosis of NOTCH3-ADCs into ligand-expressing cells. NOTCH3-ADCs internalize into receptor and ligand cells independent of signaling and induce cell death in both cell types representing an atypical mechanism of ADC cytotoxicity. Treatment of xenografts with NOTCH3-ADCs leads to sustained tumor regressions, outperforms standard-of-care chemotherapy, and allows targeting of tumors that overexpress NOTCH3 independent of signaling inhibition.
科研通智能强力驱动
Strongly Powered by AbleSci AI